DSMB case study: Decision making when a similar clinical trial is stopped early

David W. Hillman, Thomas Louis

Research output: Contribution to journalArticle

Abstract

Two similarly designed, placebo-controlled clinical trials are fully accrued and following patients for safety and outcome data. One trial is stopped at a planned interim analysis by its data safety and monitoring board (DSMB) due to a statistically significant treatment benefit. The statisticians and DSMB of the other trial are informed of these results. What are the responsibilities of the statistical center? How should the DSMB deal with the situation if the data do not support the stopped trial? What should the patients be told concerning the results of the two trials when one trial continues and the other is stopped? This DSMB case study reports on such a situation for two randomized clinical trials of oral ganciclovir for the prevention of cytomegalovirus disease in HIV/AIDS patients.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalControlled Clinical Trials
Volume24
Issue number1
DOIs
StatePublished - Feb 2003

Fingerprint

Clinical Trials Data Monitoring Committees
Decision Making
Clinical Trials
Ganciclovir
Controlled Clinical Trials
Patient Safety
Cytomegalovirus
Acquired Immunodeficiency Syndrome
Randomized Controlled Trials
Placebos
HIV

Keywords

  • Clinical trial
  • Data and Safety Monitoring Board (DSMB)
  • Interim monitoring

ASJC Scopus subject areas

  • Pharmacology

Cite this

DSMB case study : Decision making when a similar clinical trial is stopped early. / Hillman, David W.; Louis, Thomas.

In: Controlled Clinical Trials, Vol. 24, No. 1, 02.2003, p. 85-91.

Research output: Contribution to journalArticle

@article{536c1ee31b074a749bf31d7834f7a135,
title = "DSMB case study: Decision making when a similar clinical trial is stopped early",
abstract = "Two similarly designed, placebo-controlled clinical trials are fully accrued and following patients for safety and outcome data. One trial is stopped at a planned interim analysis by its data safety and monitoring board (DSMB) due to a statistically significant treatment benefit. The statisticians and DSMB of the other trial are informed of these results. What are the responsibilities of the statistical center? How should the DSMB deal with the situation if the data do not support the stopped trial? What should the patients be told concerning the results of the two trials when one trial continues and the other is stopped? This DSMB case study reports on such a situation for two randomized clinical trials of oral ganciclovir for the prevention of cytomegalovirus disease in HIV/AIDS patients.",
keywords = "Clinical trial, Data and Safety Monitoring Board (DSMB), Interim monitoring",
author = "Hillman, {David W.} and Thomas Louis",
year = "2003",
month = "2",
doi = "10.1016/S0197-2456(02)00274-X",
language = "English (US)",
volume = "24",
pages = "85--91",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - DSMB case study

T2 - Decision making when a similar clinical trial is stopped early

AU - Hillman, David W.

AU - Louis, Thomas

PY - 2003/2

Y1 - 2003/2

N2 - Two similarly designed, placebo-controlled clinical trials are fully accrued and following patients for safety and outcome data. One trial is stopped at a planned interim analysis by its data safety and monitoring board (DSMB) due to a statistically significant treatment benefit. The statisticians and DSMB of the other trial are informed of these results. What are the responsibilities of the statistical center? How should the DSMB deal with the situation if the data do not support the stopped trial? What should the patients be told concerning the results of the two trials when one trial continues and the other is stopped? This DSMB case study reports on such a situation for two randomized clinical trials of oral ganciclovir for the prevention of cytomegalovirus disease in HIV/AIDS patients.

AB - Two similarly designed, placebo-controlled clinical trials are fully accrued and following patients for safety and outcome data. One trial is stopped at a planned interim analysis by its data safety and monitoring board (DSMB) due to a statistically significant treatment benefit. The statisticians and DSMB of the other trial are informed of these results. What are the responsibilities of the statistical center? How should the DSMB deal with the situation if the data do not support the stopped trial? What should the patients be told concerning the results of the two trials when one trial continues and the other is stopped? This DSMB case study reports on such a situation for two randomized clinical trials of oral ganciclovir for the prevention of cytomegalovirus disease in HIV/AIDS patients.

KW - Clinical trial

KW - Data and Safety Monitoring Board (DSMB)

KW - Interim monitoring

UR - http://www.scopus.com/inward/record.url?scp=0037307422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037307422&partnerID=8YFLogxK

U2 - 10.1016/S0197-2456(02)00274-X

DO - 10.1016/S0197-2456(02)00274-X

M3 - Article

C2 - 12559646

AN - SCOPUS:0037307422

VL - 24

SP - 85

EP - 91

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 1

ER -